{"id":34285,"date":"2022-09-20T13:18:28","date_gmt":"2022-09-20T05:18:28","guid":{"rendered":"http:\/\/biopioneer.com.tw\/?p=34285"},"modified":"2025-11-15T16:18:36","modified_gmt":"2025-11-15T08:18:36","slug":"tapi-1-cas171235-71-5-apexbio-%e8%b2%a8%e8%99%9f-b4686","status":"publish","type":"post","link":"http:\/\/biopioneer.com.tw\/?p=34285","title":{"rendered":"TAPI-1 | CAS#171235-71-5 APExBIO \u8ca8\u865f B4686"},"content":{"rendered":"

\u816b\u7624\u58de\u6b7b\u56e0\u5b50\u6291\u5236\u5291\u7cfb\u5217\u5546\u54c1->>TAPI-1<\/span><\/span><\/span><\/span><\/strong><\/p>\n

APExBIO Technology LLC \u662f\u4e00\u5bb6\u9818\u5148\u7684\u5c0f\u5206\u5b50\u6291\u5236\u5291 (Small Molecule Inhibitors)\/\u6d3b\u5316\u5291(Activators)\u3001\u5316\u5408\u7269\u5eab( Compound Libraries)\u3001\u80dc\u80bd(Peptides)\u3001\u6aa2\u6e2c\u8a66\u5291\u76d2(Assay Kits)\u3001\u87a2\u5149\u6a19\u8a18(Fluorescent Label)\u3001\u9176(Enzymes)\u3001\u4fee\u98fe\u6838\u82f7\u9178(Modified Nucleotides)\u3001mRNA \u5408\u6210\u4ee5\u53ca\u5404\u7a2e\u5206\u5b50\u751f\u7269\u5b78\u5de5\u5177\u7684\u4f9b\u61c9\u5546\u3002APExBIO\u63d0\u4f9b\u5ee3\u6cdb\u7684\u7522\u54c1\u7dda\uff0c\u6db5\u84cb 20 \u591a\u500b\u4e0d\u540c\u7684\u7814\u7a76\u9818\u57df\uff0c\u4f8b\u5982\u764c\u75c7(cancer)\u3001\u514d\u75ab\u5b78(immunology)\u3001\u795e\u7d93\u79d1\u5b78(neurosciences)\u3001\u7d30\u80de\u51cb\u4ea1(apoptosis)\u548c\u8868\u89c0\u907a\u50b3\u5b78(epigenetics)\u7b49\u3002\u516c\u53f8\u7e3d\u90e8\u4f4d\u65bc\u7f8e\u570b\u5fb7\u5dde\u4f11\u58eb\u9813USA (Houston, Texas)\uff0c\u81f4\u529b\u65bc\u670d\u52d9\u5168\u7403\u5ba2\u6236\u3002\u9ad8\u5ea6\u91cd\u8996\u7522\u54c1\u54c1\u8cea\u3002\u6240\u6709\u7522\u54c1\u5747\u9075\u5faa\u56b4\u683c\u7684\u751f\u7522\u6307\u5357\uff0c\u4e26\u9644\u6709\u5206\u6790\u8b49\u66f8\u3001HPLC\u3001\u8cea\u8b5c(Mass Spectrum)\u548cHMNR\u4ee5\u53ca\u9ad4\u5916\u9a57\u8b49(in vitro validation)\u3002 APExBIO\u7522\u54c1\u5df2\u88ab\u300aNature\u300b\u3001\u300aCell\u300b\u548c\u300aScience\u300b\u7b49\u773e\u591a\u9802\u7d1a\u540c\u884c\u8a55\u5be9\u671f\u520a\u5f15\u7528\u3002>>\u66f4\u591aAPExBio\u5546\u54c1<\/span><\/strong><\/em><\/span><\/a><\/p>\n

<\/p>\n

\u86cb\u767d\u9176(Proteases)\u4e5f\u7a31\u70ba\u80bd\u9176(peptidases)\u6216\u86cb\u767d\u6c34\u89e3\u9176(proteolytic enzymes)\uff0c\u7531\u5927\u91cf\u50ac\u5316\u80bd\u9375\u6c34\u89e3(hydrolysis)\u4e26\u96a8\u5f8c\u5c0e\u81f4\u86cb\u767d\u8cea\u5e95\u7269(protein substrates)\u964d\u89e3\u70ba\u6c28\u57fa\u9178(amino acids)\u7684\u9176\u7d44\u6210\u3002\u86cb\u767d\u9176(Proteases)\u8207\u591a\u7a2e\u4eba\u985e\u75be\u75c5\u6709\u95dc\uff0c\u5305\u62ec\u764c\u75c7(cancer)\u3001\u795e\u7d93\u9000\u884c\u6027\u75be\u200b\u200b\u75c5(neurodegenerative disorders)\u3001\u708e\u75c7\u6027\u75be\u75c5(inflammatory diseases)\u548c\u5fc3\u8840\u7ba1\u75be\u75c5(cardiovascular diseases)\u3002\u56e0\u6b64\uff0c\u8a31\u591a\u86cb\u767d\u9176\u6291\u5236\u5291\u3010\u5c0f\u5206\u5b50(small molecules)\u548c\u86cb\u767d\u8cea\u3011\u5df2\u88ab\u9451\u5b9a\u70ba\u963b\u65b7\u86cb\u767d\u9176\u7684\u6d3b\u6027(proteases)\u3002\u86cb\u767d\u9176\u6291\u5236\u5291\u53ef\u4ee5\u6839\u64da\u5b83\u5011\u901a\u904e\u5169\u7a2e\u4e00\u822c\u6a5f\u5236\u6291\u5236\u7684\u86cb\u767d\u9176\u985e\u5225\u5206\u70ba\u4e0d\u540c\u7684\u985e\u578b\uff0c\u5373\u4e0d\u53ef\u9006\u7684\u201c\u6355\u7372(trapping)\u201d\u53cd\u61c9\u548c\u53ef\u9006(reversible)\u7684\u7dca\u5bc6\u7d50\u5408\u53cd\u61c9\u3002\u86cb\u767d\u9176\u6291\u5236\u5291\u5df2\u88ab\u7528\u4f5c\u6cbb\u7642\u86cb\u767d\u9176\u76f8\u95dc\u75be\u75c5\u7684\u8a3a\u65b7\u5291(diagnostic)\u6216\u6cbb\u7642\u5291(therapeutic agents)\u3002<\/p>\n

TAPI-1 | CAS#171235-71-5 APExBIO\u00a0 \u8ca8\u865f\u00a0B4686<\/span><\/span><\/strong><\/span><\/a><\/span><\/p>\n

TACE\/ADAM17 inhibitor Product Citation+3<\/p>\n

\"\"<\/p>\n

TAPI-1 \u662f\u4e00\u7a2e\u816b\u7624\u58de\u6b7b\u56e0\u5b50\u6291\u5236\u5291(Tumour necrosis factor)\uff0cIC50 \u503c\u70ba 8.09 \u03bcM [1]\u3002TAPI-1 \u662f TACE\/ADAM17 \u7684\u6291\u5236\u5291\uff0c\u53ef\u50ac\u5316\u5168\u9577 APP \u88c2\u89e3\u70ba\u53ef\u6eb6\u6027 N \u7aef\u7247\u6bb5 (sAPP\u03b1)\u3002\u64da\u5831\u5c0e\uff0csAPP\u03b1 \u7684\u91cb\u653e\u662f\u901a\u904e\u523a\u6fc0\u6bd2\u8548\u9e7c\u53d7\u9ad4(muscarinic receptors)\u800c\u589e\u52a0\u7684\u53d7\u9ad4\u5076\u806f\u904e\u7a0b(receptor-coupled process)\u3002\u5728 HEK293 \u7d30\u80de\u4e2d\uff0cTAPI-1 \u7684\u8655\u7406\u5c0e\u81f4\u6291\u5236\u7531 M3 \u4e9e\u578b\u8868\u9054\u8a98\u5c0e\u7684\u589e\u52a0\u7684 sAPP\u03b1\u3002 TAPI-1\u6291\u5236M3\u589e\u52a0\u7684sAPP\u03b1\u548csAPP\u03b1\u7d44\u6210\u578b\u91cb\u653e\u7684IC50\u503c\u5206\u5225\u70ba3.61 \u03bcM\u548c8.09 \u03bcM\u3002\u9664 APP \u5916\uff0c\u9084\u767c\u73fe TAPI-1 \u5c0d TNF-\u03b1\u3001IL6R\u3001TNFRI \u548c TNFRII \u7684\u91cb\u653e\u5177\u6709\u6291\u5236\u4f5c\u7528\uff0cIC50 \u503c\u5206\u5225\u70ba 50-100\u30015-10\u30015-10 \u548c 25-50 mM [1 , 2]\u3002<\/p>\n

    \n
  1. Zhang Y, Wang Y, et al. “Angiotensin \u2161 deteriorates advanced atherosclerosis by promoting MerTK cleavage and impairing efferocytosis through AT1R\/ROS\/p38MAPK\/ADAM17 pathway.” Am J Physiol Cell Physiol. 2019 Aug 7.PMID:31390228<\/a><\/li>\n
  2. Zhou J, Sun J, et al. “MicroRNA-145 overexpression attenuates apoptosis and increases matrix synthesis in nucleus pulposus cells.” Life Sci. 2019 Mar 15;221:274-283.PMID:30797016<\/a><\/li>\n
  3. Ellis-Connell AL, Balgeman AJ, et al. “ALT-803 transiently reduces SIV replication in the absence of antiretroviral treatment.” J Virol. 2017 Nov 8. pii: JVI.01748-17.PMID:29118125<\/a><\/li>\n<\/ol>\n

    \"\"<\/p>\n

    \"\"<\/p>\n

    \"\"<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
    Physical Appearance<\/td>\nA solid<\/td>\n<\/tr>\n
    Storage<\/td>\nStore at -20\u00b0C<\/td>\n<\/tr>\n
    M.Wt<\/td>\n499.6<\/td>\n<\/tr>\n
    Cas No.<\/td>\n171235-71-5<\/td>\n<\/tr>\n
    Formula<\/td>\nC26<\/sub>H37<\/sub>N5<\/sub>O5<\/sub><\/td>\n<\/tr>\n
    Solubility<\/td>\n\u226524.98 mg\/mL in DMSO; \u226515.77 mg\/mL in EtOH with ultrasonic; \u226518.1 mg\/mL in H2O<\/td>\n<\/tr>\n
    Chemical Name<\/td>\nN1-((R)-1-(((R)-1-((2-aminoethyl)amino)-1-oxopropan-2-yl)amino)-3-(naphthalen-2-yl)-1-oxopropan-2-yl)-N4-hydroxy-2-isobutylsuccinamide<\/td>\n<\/tr>\n
    SDF<\/td>\nDownload SDF<\/a><\/td>\n<\/tr>\n
    Canonical SMILES<\/td>\nNCCNC([C@@H](C)NC([C@H](NC(C(CC(C)C)CC(NO)=O)=O)CC1=CC2=CC=CC=C2C=C1)=O)=O<\/td>\n<\/tr>\n
    Shipping Condition<\/td>\nShip with blue ice, or upon other requests.<\/td>\n<\/tr>\n
    General tips<\/td>\nFor obtaining a higher solubility, please warm the tube at 37\u00b0C and shake it in the ultrasonic bath for a while. We do not recommend long-term storage for the solution, please use it up soon.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    <\/p>\n

    APExBIO\u53f0\u7063\u4ee3\u7406\u5546:\u00a0 <\/span><\/span><\/strong><\/span><\/a>https:\/\/www.apexbt.com\/<\/span><\/span><\/a><\/span><\/p>\n

    APExBIO\u63d0\u4f9b\u512a\u8cea\u7684\u80dc\u80bd\u548c\u751f\u7269\u5206\u6790\u8a66\u5291\uff0c\u5ee3\u6cdb\u7522\u54c1\u7dda\u5982Protease\u3001Chromatin\/Epigenetics\u8868\u89c0\u907a\u50b3\u5b78\u3001MAPK Signal\u3001DNA Damege\/DNA repair\u3001\u7d30\u80de\u51cb\u4ea1\u3001\u816b\u7624\u751f\u7269\u5b78\u3001Stem cell\u7b49\u7814\u7a76\u9818\u57df\uff0c \u9084\u63d0\u4f9b\u5b9a\u5236\u7684\u670d\u52d9\uff0c\u5305\u62ec\u591a\u80bd\u5408\u6210\uff0c\u6297\u9ad4\u7684\u751f\u7522\u548c\u6aa2\u6e2c\u7684\u767c\u5c55\u3002\u7522\u54c1\u7ddaDNA\/RNA prep kit\u3001Drug Screening panel\u3001Bioactive peptides\u3001Growth factors\u3001Biotinylation Reagents\u3001tag peptides\u3001amino Acids\u3001Growth factors\u7b49\u3002APExBIO\u7522\u54c1\u8cea\u91cf\u90fd\u4f34\u96a8\u8457\u8b49\u66f8\u7684\u5206\u6790\uff0c\u9ad8\u6548\u6db2\u76f8\u8272\u8b5c\uff0c\u8cea\u8b5c\uff0c\u548cHMNR\u6578\u64da\u3002<\/p>\n

    <\/p>\n\n\n\n\n\n\n\n\n\n\n\n
    \u54c1\u9805<\/td>\nCAS#<\/td>\n#\u8ca8\u865f<\/td>\n\u61c9\u7528<\/td>\n<\/tr>\n
    Z-VAD-FMK \u00a0<\/a><\/td>\nCAS# 187389-52-2<\/td>\n\u8ca8\u865f\u00a0A1902<\/td>\n\n

    Proteases<\/p>\n

    ICE-like proteases<\/td>\n<\/tr>\n

    TAPI-1 \u00a0<\/a><\/td>\nCAS#171235-71-5<\/td>\n\u8ca8\u865f\u00a0B4686<\/td>\n\n

    Proteases<\/p>\n

    TACE\/ADAM17 inhibitor Product Citation+3<\/td>\n<\/tr>\n

    Talabostat mesylate<\/a><\/td>\nCAS# 150080-09-4<\/td>\n\u8ca8\u865fB3941<\/td>\n\n

    Proteases<\/p>\n

    DPP4 \u4e8c\u80bd\u57fa\u80bd\u9176\u7279\u7570\u6027\u6291\u5236\u5291<\/td>\n<\/tr>\n

    Z-IETD-FMK<\/a><\/td>\nCAS# 210344-98-2<\/td>\n\u8ca8\u865fB3232<\/td>\ninhibitor of caspase 8<\/td>\n<\/tr>\n
    Cisplatin<\/td>\nCAS# 15663-27-1<\/td>\n\u8ca8\u865fA8321<\/td>\n\u9ad8\u6548\u3001\u5ee3\u8b5c\u7684\u5316\u7642\u85e5\u7269<\/td>\n<\/tr>\n
    17-DMAG (Alvespimycin) HCl<\/a><\/td>\nCAS#467214-21-7<\/td>\n\u00a0\u8ca8\u865fA2213<\/td>\nHsp90 inhibitor<\/td>\n<\/tr>\n
    CA-074 Me\u00a0<\/a><\/td>\nCAS# 147859-80-1<\/td>\n\u8ca8\u865fA8239<\/td>\nCathepsin B inhibitor<\/td>\n<\/tr>\n
    VX-765<\/a><\/td>\nCAS# 273404-37-8<\/td>\n\u8ca8\u865fA8238<\/td>\nCaspase-1 inhibitor<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

     <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
    A3608<\/td>\nMK 0893<\/td>\n870823-12-4<\/td>\n98.58%<\/td>\nGlucagon receptor\/IGF-1R antagonist<\/td>\n<\/tr>\n
    A3609<\/td>\nMK-0591<\/td>\n136668-42-3<\/td>\n98.00%<\/td>\nFLAP inhibitor,potent and selective<\/td>\n<\/tr>\n
    A3611<\/td>\nMK-0812<\/td>\n624733-88-6<\/td>\n98.00%<\/td>\nantagonist of chemokine receptor CCR-2<\/td>\n<\/tr>\n
    A3612<\/td>\nMK-0974<\/td>\n781649-09-0<\/td>\n98.00%<\/td>\nCGRP receptor antagonist<\/td>\n<\/tr>\n
    A3613<\/td>\nMK-2894<\/td>\n1006036-87-8<\/td>\n98.00%<\/td>\nEP4 receptor inhibitor<\/td>\n<\/tr>\n
    A3615<\/td>\nMK-3207<\/td>\n957118-49-9<\/td>\n98.00%<\/td>\nCGRP receptor antagonist<\/td>\n<\/tr>\n
    A3617<\/td>\nMK-4827<\/td>\n1038915-60-4<\/td>\n98.93%<\/td>\nPARP-1\/-2 inhibitor,potent and selective<\/td>\n<\/tr>\n
    A3618<\/td>\nMK-5172<\/td>\n1350514-68-9<\/td>\n99.79%<\/td>\nHCV NS3\/4a protease inhibitor<\/td>\n<\/tr>\n
    A3619<\/td>\nMK-5172 hydrate<\/td>\n1350462-55-3<\/td>\n98.00%<\/td>\nHCV NS3\/4a protease inhibitor<\/td>\n<\/tr>\n
    A3620<\/td>\nMK-5172 potassium salt<\/td>\n1206524-86-8<\/td>\n98.00%<\/td>\nHCV NS3\/4a protease inhibitor<\/td>\n<\/tr>\n
    A3621<\/td>\nMK-5172 sodium salt<\/td>\n1425038-27-2<\/td>\n98.00%<\/td>\nHCV NS3\/4a protease inhibitor<\/td>\n<\/tr>\n
    A3623<\/td>\nMK-6892<\/td>\n917910-45-3<\/td>\n99.65%<\/td>\nHighly potential GPR109A agonist<\/td>\n<\/tr>\n
    A3624<\/td>\nMK-8033<\/td>\n1001917-37-8<\/td>\n98.00%<\/td>\nC-MET inhibitor<\/td>\n<\/tr>\n
    A3626<\/td>\nML-7 hydrochloride<\/td>\n110448-33-4<\/td>\n98.43%<\/td>\nMyosin light chain kinase inhibitor<\/td>\n<\/tr>\n
    A3627<\/td>\nMLN 2480<\/td>\n1096708-71-2<\/td>\n98.99%<\/td>\nPan-Raf kinase inhibitor,investigational<\/td>\n<\/tr>\n
    A3628<\/td>\nMLN120B<\/td>\n783348-36-7<\/td>\n99.82%<\/td>\nI\u03baB Kinase \u03b2 Inhibitor<\/td>\n<\/tr>\n
    A3629<\/td>\nMLN4924 HCl salt<\/td>\n1160295-21-5<\/td>\n98.00%<\/td>\nNAE inhibitor<\/td>\n<\/tr>\n
    A3630<\/td>\nMMAD<\/td>\n203849-91-6<\/td>\n98.00%<\/td>\nTubulin inhibitor,highly potent<\/td>\n<\/tr>\n
    A3631<\/td>\nMonomethyl auristatin E<\/td>\n474645-27-7<\/td>\n98.34%<\/td>\nAntimitotic agent<\/td>\n<\/tr>\n
    A3632<\/td>\nMotesanib<\/td>\n453562-69-1<\/td>\n98.00%<\/td>\nInhibitor of Flk-1\/Flt-4\/PDGFR-\/c-Kit<\/td>\n<\/tr>\n
    A3633<\/td>\nMPEP Hydrochloride<\/td>\n219911-35-0<\/td>\n98.00%<\/td>\nMGlu5 receptor antagonist<\/td>\n<\/tr>\n
    A3634<\/td>\nMPTP hydrochloride<\/td>\n23007-85-4<\/td>\n99.79%<\/td>\nDopaminergic neurotoxin,induced reduction in the DOPAC HVA\/dopamine (DA) ratio<\/td>\n<\/tr>\n
    A3636<\/td>\nMTEP hydrochloride<\/td>\n1186195-60-7<\/td>\n98.00%<\/td>\nMGlu5 antagonist<\/td>\n<\/tr>\n
    A3637<\/td>\nGDC-mTOR inhibitor<\/td>\n1207358-59-5<\/td>\n98.00%<\/td>\nMTOR inhibitor<\/td>\n<\/tr>\n
    A3641<\/td>\nNaphthoquine phosphate<\/td>\n173531-58-3<\/td>\n98.00%<\/td>\nAntimalarial drug<\/td>\n<\/tr>\n
    A3642<\/td>\nNarciclasine<\/td>\n29477-83-6<\/td>\n98.00%<\/td>\nModulates the Rho\/ROCK\/LIM kinase\/cofilin pathway<\/td>\n<\/tr>\n
    A3643<\/td>\nNarlaprevir<\/td>\n865466-24-6<\/td>\n98.00%<\/td>\nHCV NS3 protease inhibitor<\/td>\n<\/tr>\n
    A3645<\/td>\nNB-598<\/td>\n131060-14-5<\/td>\n99.35%<\/td>\nSE inhibitor<\/td>\n<\/tr>\n
    A3646<\/td>\nNB-598 hydrochloride<\/td>\n136719-25-0<\/td>\n98.00%<\/td>\nSE inhibitor<\/td>\n<\/tr>\n
    A3647<\/td>\nNB-598 Maleate<\/td>\n155294-62-5<\/td>\n98.97%<\/td>\nSqualene epoxidase inhibitor<\/td>\n<\/tr>\n
    A3649<\/td>\nNBD-556<\/td>\n333353-44-9<\/td>\n98.00%<\/td>\nHIV-1 entry inhibitor,CD4 mimetic,block gp120-CD4 interaction<\/td>\n<\/tr>\n
    A3652<\/td>\nNecrostatin 2<\/td>\n852391-19-6<\/td>\n98.00%<\/td>\nIn vitro necroptosis inhibitor<\/td>\n<\/tr>\n
    A3653<\/td>\nNelfinavir Mesylate<\/td>\n159989-65-8<\/td>\n98.04%<\/td>\nHIV protease inhibitor,antiretroviral drug for HIV treatment<\/td>\n<\/tr>\n
    A3655<\/td>\nNesbuvir<\/td>\n691852-58-1<\/td>\n99.79%<\/td>\nNS5B polymerase inhibitor<\/td>\n<\/tr>\n
    A3658<\/td>\nNG25<\/td>\n1315355-93-1<\/td>\n98.00%<\/td>\nTAK1 inhibitor<\/td>\n<\/tr>\n
    A3659<\/td>\nNifuratel<\/td>\n4936-47-4<\/td>\n98.00%<\/td>\nAntibacterial, antifungal, and antiprotozoal compound<\/td>\n<\/tr>\n
    A3660<\/td>\nNilotinib monohydrochloride monohydrate<\/td>\n923288-90-8<\/td>\n99.89%<\/td>\nBcr-Abl inhibitor<\/td>\n<\/tr>\n
    A3662<\/td>\nNNC 55-0396<\/td>\n357400-13-6<\/td>\n98.00%<\/td>\nT-type calcium channel blocker<\/td>\n<\/tr>\n
    A3663<\/td>\nNoopept<\/td>\n157115-85-0<\/td>\n98.00%<\/td>\nNootropic and neuroprotective agent<\/td>\n<\/tr>\n
    A3664<\/td>\nNordihydroguaiaretic acid<\/td>\n500-38-9<\/td>\n99.83%<\/td>\nAnti-tumor agent;lipoxygenase inhibitor<\/td>\n<\/tr>\n
    A3665<\/td>\nNortadalafil<\/td>\n171596-36-4<\/td>\n98.00%<\/td>\nPDE5 inhibitor<\/td>\n<\/tr>\n
    A3666<\/td>\nNP118809<\/td>\n41332-24-5<\/td>\n98.00%<\/td>\nN-type calcium channel blocker<\/td>\n<\/tr>\n
    A3667<\/td>\nNPS-2143 hydrochloride<\/td>\n324523-20-8<\/td>\n99.89%<\/td>\nCalcium ion-sensing receptor antagonist<\/td>\n<\/tr>\n
    A3668<\/td>\nNS309<\/td>\n18711-16-5<\/td>\n98.00%<\/td>\nCalcium-Activated Potassium Channel activator<\/td>\n<\/tr>\n
    A3670<\/td>\nNucleozin<\/td>\n341001-38-5<\/td>\n99.55%<\/td>\nTargets influenza A nucleoprotein (NP),cell-permeable isoxazolylpiperazine compound<\/td>\n<\/tr>\n
    A3671<\/td>\nNutlin-3a chiral<\/td>\n675576-98-4<\/td>\n98.39%<\/td>\nMDM2 inhibitor, antiproliferative and antiproapoptotic<\/td>\n<\/tr>\n
    A3672<\/td>\nNVP-BAG956<\/td>\n853910-02-8<\/td>\n98.00%<\/td>\nPI3K and PDK1 inhibitor<\/td>\n<\/tr>\n
    A3673<\/td>\nNVP-BGJ398 phosphate<\/td>\n1310746-10-1<\/td>\n99.78%<\/td>\nFGFR inhibitor<\/td>\n<\/tr>\n
    A3674<\/td>\nNVP-BKM120 Hydrochloride<\/td>\n1312445-63-8<\/td>\n98.02%<\/td>\nPI3K inhibitor<\/td>\n<\/tr>\n
    A3675<\/td>\nNVP-BSK805<\/td>\n1092499-93-8<\/td>\n98.00%<\/td>\nATP-competitive JAK2 inhibitor<\/td>\n<\/tr>\n
    A3676<\/td>\nNVP-LCQ195<\/td>\n902156-99-4<\/td>\n97.50%<\/td>\nCDK1\/CDK2\/CDK5 inhibitor<\/td>\n<\/tr>\n
    A3680<\/td>\nOlcegepant<\/td>\n204697-65-4<\/td>\n97.46%<\/td>\nNon-peptide receptor of CGRP,first potent and selective<\/td>\n<\/tr>\n
    A3681<\/td>\nOlmesartan<\/td>\n144689-24-7<\/td>\n99.20%<\/td>\nAngiotensin II receptor antagonist<\/td>\n<\/tr>\n
    A3683<\/td>\nOlprinone Hydrochloride<\/td>\n119615-63-3<\/td>\n99.74%<\/td>\nPhosphodiesterase 3 (PDE3) inhibitor, selective<\/td>\n<\/tr>\n
    A3684<\/td>\nONO-AE3-208<\/td>\n402473-54-5<\/td>\n97.73%<\/td>\nEP4 receptor antagonist,high affinity and selective<\/td>\n<\/tr>\n
    A3686<\/td>\nOrteronel<\/td>\n566939-85-3<\/td>\n98.00%<\/td>\nFor castration-resistant prostate cancer, clinical candidate<\/td>\n<\/tr>\n
    A3688<\/td>\nOseltamivir<\/td>\n196618-13-0<\/td>\n96.83%<\/td>\ninhibitor of influenza neuraminidase<\/td>\n<\/tr>\n
    A3689<\/td>\nOseltamivir acid<\/td>\n187227-45-8<\/td>\n99.08%<\/td>\nInfluenza neuraminidase inhibitor<\/td>\n<\/tr>\n
    A3690<\/td>\nOtamixaban<\/td>\n193153-04-7<\/td>\n98.00%<\/td>\nDirect factor Xa inhibitors,potent and selective<\/td>\n<\/tr>\n
    A3691<\/td>\nOtenabant<\/td>\n686344-29-6<\/td>\n98.00%<\/td>\nCB1 receptor antagonist<\/td>\n<\/tr>\n
    A3692<\/td>\nOTX-015<\/td>\n202590-98-5<\/td>\n99.57%<\/td>\nBRD inhibitor<\/td>\n<\/tr>\n
    A3695<\/td>\nPafuramidine<\/td>\n186953-56-0<\/td>\n98.00%<\/td>\nProdrug of furamidine<\/td>\n<\/tr>\n
    A3696<\/td>\nPalifosfamide<\/td>\n31645-39-3<\/td>\n98.00%<\/td>\nActive metabolite of ifosfamide (IFOS)<\/td>\n<\/tr>\n
    A3697<\/td>\nPalonosetron<\/td>\n135729-61-2<\/td>\n98.00%<\/td>\n5-HT3 antagonist<\/td>\n<\/tr>\n
    A3700<\/td>\nParadol<\/td>\n27113-22-0<\/td>\n98.00%<\/td>\nActive flavor constituent of the seeds of Guinea pepper<\/td>\n<\/tr>\n
    A3702<\/td>\nParicalcitol<\/td>\n131918-61-1<\/td>\n98.00%<\/td>\nAnalog of VD2 active form<\/td>\n<\/tr>\n
    A3704<\/td>\nPD 123319 ditrifluoroacetate<\/td>\n136676-91-0<\/td>\n99.14%<\/td>\nAngiotensin AT2 receptor antagonist<\/td>\n<\/tr>\n
    A3706<\/td>\nPDK1 inhibitor<\/td>\n1001409-50-2<\/td>\n98.00%<\/td>\nPDK1 inhibitor<\/td>\n<\/tr>\n
    A3707<\/td>\nPemetrexed disodium hemipenta hydrate<\/td>\n357166-30-4<\/td>\n99.94%<\/td>\nAntifolate and antimetabolite agent<\/td>\n<\/tr>\n
    A3708<\/td>\nPentostatin<\/td>\n53910-25-1<\/td>\n99.05%<\/td>\nIrreversible adenosine deaminase inhibitor<\/td>\n<\/tr>\n
    A3709<\/td>\nPeramivir<\/td>\n330600-85-6<\/td>\n99.01%<\/td>\nAeuraminidase inhibitor;antiviral drug<\/td>\n<\/tr>\n
    A3711<\/td>\nPF-03084014<\/td>\n865773-15-5<\/td>\n98.52%<\/td>\n\u03b3-secretase inhibitor<\/td>\n<\/tr>\n
    A3712<\/td>\nPF-04217903 methanesulfonate<\/td>\n956906-93-7<\/td>\n98.00%<\/td>\nC-Met inhibitor,selective and ATP-competitive<\/td>\n<\/tr>\n
    A3715<\/td>\nPF-04971729<\/td>\n1210344-57-2<\/td>\n98.00%<\/td>\nSGLT inhibitor<\/td>\n<\/tr>\n
    A3716<\/td>\nPF-3758309<\/td>\n898044-15-0<\/td>\n98.39%<\/td>\nPAK4 inhibitor<\/td>\n<\/tr>\n
    A3717<\/td>\nPF-543<\/td>\n1415562-82-1<\/td>\n99.32%<\/td>\nSphK1 inhibitor,cell-permeate,potent and selective<\/td>\n<\/tr>\n
    A3718<\/td>\nPF-543 Citrate<\/td>\n1415562-83-2<\/td>\n98.95%<\/td>\nSphK1 inhibitor,potent and cell-permeate<\/td>\n<\/tr>\n
    A3719<\/td>\nPF-670462<\/td>\n950912-80-8<\/td>\n99.66%<\/td>\nCK1 \u03b5\/\u03b4 inhibitor<\/td>\n<\/tr>\n
    A3720<\/td>\nPF-8380<\/td>\n1144035-53-9<\/td>\n98.23%<\/td>\nAutotaxin inhibitor,potent and specific<\/td>\n<\/tr>\n
    A3721<\/td>\nPHA-767491<\/td>\n845714-00-3<\/td>\n99.03%<\/td>\nCdc7\/cdk9 inhibitor, potent, ATP-competitive<\/td>\n<\/tr>\n
    A3722<\/td>\nPhenylpiracetam<\/td>\n77472-70-9<\/td>\n99.21%<\/td>\nNootropic derivative of piracetam<\/td>\n<\/tr>\n
    A3723<\/td>\nPhloretin<\/td>\n60-82-2<\/td>\n99.12%<\/td>\nA dihydrochalcone found in apple<\/td>\n<\/tr>\n
    A3724<\/td>\nPI-103 Hydrochloride<\/td>\n371935-79-4<\/td>\n98.00%<\/td>\nDNA-PK\/PI 3-kinase\/mTOR inhibitor<\/td>\n<\/tr>\n
    A3727<\/td>\nPitolisant hydrochloride<\/td>\n903576-44-3<\/td>\n99.71%<\/td>\nNonimidazole inverse agonist<\/td>\n<\/tr>\n
    A3729<\/td>\nPJ34<\/td>\n344458-19-1<\/td>\n95.69%<\/td>\nPARP-l inhibitor<\/td>\n<\/tr>\n
    A3730<\/td>\nPND-1186<\/td>\n1061353-68-1<\/td>\n99.75%<\/td>\nPotent FAK inhibitor<\/td>\n<\/tr>\n
    A3732<\/td>\nPoloxin<\/td>\n321688-88-4<\/td>\n98.00%<\/td>\nPLK1 inhibitor<\/td>\n<\/tr>\n
    A3733<\/td>\nPramipexole dihydrochloride<\/td>\n104632-25-9<\/td>\n98.94%<\/td>\nDopamine receptor agonist<\/td>\n<\/tr>\n
    A3735<\/td>\nPreladenant<\/td>\n377727-87-2<\/td>\n98.00%<\/td>\nAdenosine A2A receptor antagonist<\/td>\n<\/tr>\n
    A3736<\/td>\nPRT062607 Hydrochloride<\/td>\n1370261-97-4<\/td>\n98.63%<\/td>\nSYK inhibitor,potent and selective<\/td>\n<\/tr>\n
    A3738<\/td>\nPSI-7977<\/td>\n1190307-88-0<\/td>\n99.81%<\/td>\nAntiviral agents for chronic HCV infection<\/td>\n<\/tr>\n
    A3740<\/td>\nPuromycin aminonucleoside<\/td>\n58-60-6<\/td>\n98.19%<\/td>\nAminonucleoside portion of the antibiotic puromycin<\/td>\n<\/tr>\n
    A3741<\/td>\nPyridone 6<\/td>\n457081-03-7<\/td>\n99.60%<\/td>\nPan-JAK inhibitor<\/td>\n<\/tr>\n
    A3742<\/td>\nPyridostatin<\/td>\n1085412-37-8<\/td>\n98.02%<\/td>\nDrug used for promoting growth arrest<\/td>\n<\/tr>\n
    A3744<\/td>\nQuetiapine<\/td>\n111974-69-7<\/td>\n98.00%<\/td>\nDopamine receptor antagonist<\/td>\n<\/tr>\n
    A3746<\/td>\nR1530<\/td>\n882531-87-5<\/td>\n98.00%<\/td>\nAntiangiogenesis,mitosis-angiogenesis inhibitor (MAI)<\/td>\n<\/tr>\n
    A3747<\/td>\nR-7128<\/td>\n940908-79-2<\/td>\n98.00%<\/td>\nNS5B inhibitor<\/td>\n<\/tr>\n
    A3749<\/td>\nRadezolid<\/td>\n869884-78-6<\/td>\n99.32%<\/td>\nNovel oxazolidinone antibiotic agent<\/td>\n<\/tr>\n
    A3750<\/td>\nRegorafenib hydrochloride<\/td>\n835621-07-3<\/td>\n98.57%<\/td>\nTyrosine kinase inhibitor<\/td>\n<\/tr>\n
    A3752<\/td>\nReparixin<\/td>\n266359-83-5<\/td>\n98.11%<\/td>\nInhibitor of CXCL8 receptor and CXCR1\/CXCR2 activation<\/td>\n<\/tr>\n
    A3753<\/td>\nReparixin L-lysine salt<\/td>\n266359-93-7<\/td>\n97.82%<\/td>\nCXCR1\/CXCR2 inhibitor<\/td>\n<\/tr>\n
    A3754<\/td>\nRepSox<\/td>\n446859-33-2<\/td>\n99.83%<\/td>\nALK5 inhibitor,potent and selective<\/td>\n<\/tr>\n
    A3755<\/td>\nResminostat hydrochloride<\/td>\n1187075-34-8<\/td>\n98.00%<\/td>\nHDAC inhibitor<\/td>\n<\/tr>\n
    A3756<\/td>\nRetaspimycin<\/td>\n857402-23-4<\/td>\n98.00%<\/td>\nHSP90 inhibitor,antiproliferative and antineoplastic<\/td>\n<\/tr>\n
    A3758<\/td>\nRetigabine dihydrochloride<\/td>\n150812-13-8<\/td>\n99.27%<\/td>\nAntiepileptic compound<\/td>\n<\/tr>\n
    A3759<\/td>\nRetinyl glucoside<\/td>\n136778-12-6<\/td>\n98.00%<\/td>\nMetabolites of vitamin A<\/td>\n<\/tr>\n
    A3760<\/td>\nReversine<\/td>\n656820-32-5<\/td>\n99.09%<\/td>\nA3 adenosine receptor antagonist,ARK-1\/-2\/-3 inhibitor<\/td>\n<\/tr>\n
    A3761<\/td>\nRG2833<\/td>\n1215493-56-3<\/td>\n98.06%<\/td>\nBrain-penetrant HDAC inhibitor<\/td>\n<\/tr>\n
    A3762<\/td>\nRG7112<\/td>\n939981-39-2<\/td>\n98.58%<\/td>\nMDM2 inhibitor, first clinical<\/td>\n<\/tr>\n
    A3763<\/td>\nRG7388<\/td>\n1229705-06-9<\/td>\n99.82%<\/td>\nMDM2 antagonist, oral, selective<\/td>\n<\/tr>\n
    A3764<\/td>\nRI-1<\/td>\n415713-60-9<\/td>\n99.54%<\/td>\nRAD51 inhibitor,cell-permeable<\/td>\n<\/tr>\n
    A3765<\/td>\nRilpivirine<\/td>\n500287-72-9<\/td>\n99.64%<\/td>\nInhibitor of next-generation nonnucleoside reverse transcriptase<\/td>\n<\/tr>\n
    A3766<\/td>\nRimonabant hydrochloride<\/td>\n158681-13-1<\/td>\n98.01%<\/td>\nCB1 receptor inverse agonist<\/td>\n<\/tr>\n
    A3767<\/td>\nRiociguat<\/td>\n625115-55-1<\/td>\n99.77%<\/td>\nSoluble guanylate cyclase (sGC) stimulator<\/td>\n<\/tr>\n
    A3768<\/td>\nRivastigmine<\/td>\n123441-03-2<\/td>\n99.68%<\/td>\nCholinesterase inhibitor<\/td>\n<\/tr>\n
    A3770<\/td>\nRJR-2403 oxalate<\/td>\n220662-95-3<\/td>\n98.00%<\/td>\nNicotinic receptor agonist<\/td>\n<\/tr>\n
    A3771<\/td>\nRKI-1447<\/td>\n1342278-01-6<\/td>\n99.52%<\/td>\nPotent ROCK1\/ROCK2 inhibitor<\/td>\n<\/tr>\n
    A3776<\/td>\nRotigotine<\/td>\n99755-59-6<\/td>\n98.00%<\/td>\nAgonist of dopamine D2\/D3 receptor<\/td>\n<\/tr>\n
    A3777<\/td>\nRotigotine hydrochloride<\/td>\n125572-93-2<\/td>\n98.00%<\/td>\nAgonist of dopamine D2\/D3 receptor<\/td>\n<\/tr>\n
    A3778<\/td>\nRS 127445<\/td>\n199864-87-4<\/td>\n98.01%<\/td>\n5-HT2B receptor antagonist,high affinity<\/td>\n<\/tr>\n
    A3780<\/td>\nRU 58841<\/td>\n154992-24-2<\/td>\n98.40%<\/td>\nAndrogen receptor antagonist<\/td>\n<\/tr>\n
    A3781<\/td>\nRuxolitinib phosphate<\/td>\n1092939-17-7<\/td>\n98.75%<\/td>\nJAK1\/JAK2 inhibitor<\/td>\n<\/tr>\n
    A3783<\/td>\nS0859<\/td>\n1019331-10-2<\/td>\n98.00%<\/td>\nNBC inhibitor,potent and selective<\/td>\n<\/tr>\n
    A3784<\/td>\nSafinamide<\/td>\n133865-89-1<\/td>\n99.64%<\/td>\nMAO-B inhibitor<\/td>\n<\/tr>\n
    A3787<\/td>\nSalirasib<\/td>\n162520-00-5<\/td>\n99.28%<\/td>\nInhibitor of active Ras protein<\/td>\n<\/tr>\n
    A3789<\/td>\nSalmeterol xinafoate<\/td>\n94749-08-3<\/td>\n98.11%<\/td>\n\u03b22-adrenergic receptor agonist<\/td>\n<\/tr>\n
    A3790<\/td>\nSaquinavir<\/td>\n127779-20-8<\/td>\n98.00%<\/td>\nHIV Protease Inhibitor<\/td>\n<\/tr>\n
    A3791<\/td>\nSaquinavir mesylate<\/td>\n149845-06-7<\/td>\n99.75%<\/td>\nHIV Protease Inhibitor<\/td>\n<\/tr>\n
    A3792<\/td>\nSB 239063<\/td>\n193551-21-2<\/td>\n98.63%<\/td>\nP38 MAP kinase inhibitor<\/td>\n<\/tr>\n
    A3794<\/td>\nSB1317<\/td>\n937270-47-8<\/td>\n98.02%<\/td>\nCDK,JAK and FLT inhibitor<\/td>\n<\/tr>\n
    A3795<\/td>\nSB-222200<\/td>\n174635-69-9<\/td>\n98.86%<\/td>\nHuman NK-3 receptor antagonist<\/td>\n<\/tr>\n
    A3798<\/td>\nSB-408124 Hydrochloride<\/td>\n1431697-90-3<\/td>\n98.00%<\/td>\nOX1 receptor antagonist,selective and non-peptide<\/td>\n<\/tr>\n
    A3800<\/td>\nSB-674042<\/td>\n483313-22-0<\/td>\n98.00%<\/td>\nOX1 selective antagonist<\/td>\n<\/tr>\n
    A3802<\/td>\nSCH 527123<\/td>\n473727-83-2<\/td>\n99.40%<\/td>\nCXCR1 and CXCR2 receptors antagonist<\/td>\n<\/tr>\n
    A3804<\/td>\nSCH-1473759<\/td>\n1094069-99-4<\/td>\n98.00%<\/td>\nAurora A\/B inhibitor<\/td>\n<\/tr>\n
    A3805<\/td>\nSCH772984<\/td>\n942183-80-4<\/td>\n98.06%<\/td>\nERK1 and ERK2 inhibitor<\/td>\n<\/tr>\n
    A3806<\/td>\nSCH900776 S-isomer<\/td>\n891494-64-7<\/td>\n99.18%<\/td>\nCheckpoint kinase(Chk)inhibitor<\/td>\n<\/tr>\n
    A3808<\/td>\nSD-208<\/td>\n627536-09-8<\/td>\n99.11%<\/td>\nTGF-\u03b2R I kinase inhibitor<\/td>\n<\/tr>\n
    A3809<\/td>\nSDZ 220-581<\/td>\n174575-17-8<\/td>\n98.00%<\/td>\nNMDA glutamate receptor subtype antagonist<\/td>\n<\/tr>\n
    A3811<\/td>\nSEA0400<\/td>\n223104-29-8<\/td>\n99.20%<\/td>\nSpecific inhibitor of Na+\/Ca2+ exchange<\/td>\n<\/tr>\n
    A3814<\/td>\nSeocalcitol<\/td>\n134404-52-7<\/td>\n98.00%<\/td>\nVitamin D receptor agonist<\/td>\n<\/tr>\n
    A3815<\/td>\nSetiptiline<\/td>\n57262-94-9<\/td>\n98.00%<\/td>\nSerotonin receptor antagonist<\/td>\n<\/tr>\n
    A3816<\/td>\nSetiptiline maleate<\/td>\n85650-57-3<\/td>\n98.00%<\/td>\nSerotonin receptor antagonist<\/td>\n<\/tr>\n
    A3818<\/td>\nSilvestrol<\/td>\n697235-38-4<\/td>\n98.00%<\/td>\nAntineoplastic<\/td>\n<\/tr>\n
    A3820<\/td>\nSimeprevir<\/td>\n923604-59-5<\/td>\n99.42%<\/td>\nInhibitor of HCV NS3\/4A protease<\/td>\n<\/tr>\n
    A3821<\/td>\nSRT2104 (GSK2245840)<\/td>\n1093403-33-8<\/td>\n98.50%<\/td>\nSIRT1 activator,selective<\/td>\n<\/tr>\n
    A3823<\/td>\nSJB2-043<\/td>\n63388-44-3<\/td>\n99.78%<\/td>\nUSP1 inhibitor<\/td>\n<\/tr>\n
    A3824<\/td>\nSkepinone-L<\/td>\n1221485-83-1<\/td>\n99.88%<\/td>\nP38-MAPK inhibitor,potent and selective<\/td>\n<\/tr>\n
    A3825<\/td>\nSLx-2119<\/td>\n911417-87-3<\/td>\n98.80%<\/td>\nSelective ROCK2 inhibitor<\/td>\n<\/tr>\n
    A3826<\/td>\nSMIP004<\/td>\n143360-00-3<\/td>\n98.17%<\/td>\nApoptosis inducer<\/td>\n<\/tr>\n
    A3828<\/td>\nSobetirome<\/td>\n211110-63-3<\/td>\n99.01%<\/td>\nAgonist of tyroid hormone receptor<\/td>\n<\/tr>\n
    A3829<\/td>\nsodium 4-pentynoate<\/td>\n101917-30-0<\/td>\n98.00%<\/td>\nchemical reporter for the profiling of acetylated proteins<\/td>\n<\/tr>\n
    A3832<\/td>\nSolasodine<\/td>\n126-17-0<\/td>\n98.00%<\/td>\nNeuroprotective antioxidant glycoalkaloid<\/td>\n<\/tr>\n
    A3834<\/td>\nSQ109<\/td>\n502487-67-4<\/td>\n98.00%<\/td>\nAntibiotic for treatment of pulmonary TB<\/td>\n<\/tr>\n
    A3835<\/td>\nSR1078<\/td>\n1246525-60-9<\/td>\n98.65%<\/td>\nOrphan receptor agonist<\/td>\n<\/tr>\n
    A3836<\/td>\nSR3335<\/td>\n293753-05-6<\/td>\n99.52%<\/td>\nROR\u03b1 agonist,partial inverse and selective<\/td>\n<\/tr>\n
    A3837<\/td>\nDL-\u03b1-Hydroxyglutaric acid disodium salt<\/td>\n40951-21-1<\/td>\n98.00%<\/td>\nalpha hydroxy acid<\/td>\n<\/tr>\n
    A3838<\/td>\nSRT3109<\/td>\n1204707-71-0<\/td>\n98.00%<\/td>\nCXCR2 ligand<\/td>\n<\/tr>\n
    A3839<\/td>\nSRT3190<\/td>\n1204707-73-2<\/td>\n99.56%<\/td>\nCXCR2 ligand,SIRT1 activator<\/td>\n<\/tr>\n
    A3840<\/td>\nST 2825<\/td>\n894787-30-5<\/td>\n98.00%<\/td>\nInhibitor of MyD88 dimerization<\/td>\n<\/tr>\n
    A3843<\/td>\nSU 5402<\/td>\n215543-92-3<\/td>\n98.48%<\/td>\nVEGFR2\/FGFR\/PDGFR\/EGFR inhibitor<\/td>\n<\/tr>\n
    A3844<\/td>\nSU14813<\/td>\n627908-92-3<\/td>\n98.00%<\/td>\nTyrosine kinase inhibitor<\/td>\n<\/tr>\n
    A3846<\/td>\nSU14813 maleate<\/td>\n849643-15-8<\/td>\n98.00%<\/td>\nVEGFR\/PDGFR\/Kit\/FLT-3 inhibitor<\/td>\n<\/tr>\n
    A3847<\/td>\nSU5416<\/td>\n204005-46-9<\/td>\n99.06%<\/td>\nVEGF receptor inhibitor and AHR agonist<\/td>\n<\/tr>\n
    A3848<\/td>\nTacalcitol<\/td>\n57333-96-7<\/td>\n98.00%<\/td>\nPromotes normal bone development by regulating calcium<\/td>\n<\/tr>\n
    A3850<\/td>\nTAK-242<\/td>\n243984-11-4<\/td>\n99.53%<\/td>\nTLR 4 signaling inhibitor<\/td>\n<\/tr>\n
    A3853<\/td>\nTalarozole<\/td>\n201410-53-9<\/td>\n98.00%<\/td>\nCytochrome P450 inhibitor<\/td>\n<\/tr>\n
    A3854<\/td>\nTalnetant<\/td>\n174636-32-9<\/td>\n98.00%<\/td>\nNK3 receptor antagonist,potent and selective<\/td>\n<\/tr>\n
    A3856<\/td>\nTamibarotene<\/td>\n94497-51-5<\/td>\n98.41%<\/td>\nRAR\u03b1 agonist<\/td>\n<\/tr>\n
    A3857<\/td>\nTanaproget<\/td>\n304853-42-7<\/td>\n98.00%<\/td>\nProgesterone receptor agonist<\/td>\n<\/tr>\n
    A3858<\/td>\nTaranabant<\/td>\n701977-09-5<\/td>\n98.00%<\/td>\nCannabinoid receptor type 1 inverse agonist<\/td>\n<\/tr>\n
    A3859<\/td>\nTariquidar methanesulfonate, hydrate<\/td>\n625375-83-9<\/td>\n99.49%<\/td>\nP-glycoprotein inhibitor, potent and selective<\/td>\n<\/tr>\n
    A3860<\/td>\nTasquinimod<\/td>\n254964-60-8<\/td>\n99.47%<\/td>\nAntiangiogenic and antineoplastic agent<\/td>\n<\/tr>\n
    A3861<\/td>\nTBB<\/td>\n17374-26-4<\/td>\n99.23%<\/td>\nCasein kinase-2 (CK2) inhibitor<\/td>\n<\/tr>\n
    A3862<\/td>\nTC-DAPK 6<\/td>\n315694-89-4<\/td>\n98.00%<\/td>\nDAPK inhibitor<\/td>\n<\/tr>\n
    A3863<\/td>\nTedizolid<\/td>\n856866-72-3<\/td>\n99.63%<\/td>\nOxazolidinone for gram-positive infections<\/td>\n<\/tr>\n
    A3864<\/td>\nTegobuvir<\/td>\n1000787-75-6<\/td>\n98.97%<\/td>\nHCV RNA replication inhibitor<\/td>\n<\/tr>\n
    A3865<\/td>\nTeneligliptin hydrobromide<\/td>\n906093-29-6<\/td>\n99.90%<\/td>\nDipeptidyl peptidase-4 inhibitor<\/td>\n<\/tr>\n
    A3870<\/td>\nTG 100801<\/td>\n867331-82-6<\/td>\n98.00%<\/td>\nMulti-kinase inhibitor<\/td>\n<\/tr>\n
    A3872<\/td>\nTH-302<\/td>\n918633-87-1<\/td>\n98.40%<\/td>\nHypoxia-activated prodrug,inhibits H460\/HT29 cell growth<\/td>\n<\/tr>\n
    A3873<\/td>\nTianeptine<\/td>\n66981-73-5; 72797-41-2<\/td>\n99.46%<\/td>\n5-HT facilitator<\/td>\n<\/tr>\n
    A3874<\/td>\nTiotropium Bromide<\/td>\n136310-93-5<\/td>\n99.39%<\/td>\nMAChR M antagonist<\/td>\n<\/tr>\n
    A3875<\/td>\nTipiracil hydrochloride<\/td>\n183204-72-0<\/td>\n99.74%<\/td>\nThymidine phosphorylase inhibitor<\/td>\n<\/tr>\n
    A3876<\/td>\nTipranavir<\/td>\n174484-41-4<\/td>\n98.00%<\/td>\nHIV protease inhibitor<\/td>\n<\/tr>\n
    A3877<\/td>\nTirofiban hydrochloride monohydrate<\/td>\n150915-40-5<\/td>\n99.46%<\/td>\nGlycoprotein IIb\/IIIa inhibitor<\/td>\n<\/tr>\n
    A3878<\/td>\nTMC353121<\/td>\n857066-90-1<\/td>\n98.00%<\/td>\nPotent RSV fusion inhibitor<\/td>\n<\/tr>\n
    A3879<\/td>\nToceranib<\/td>\n356068-94-5<\/td>\n98.00%<\/td>\nc-Kit\/VEGFR\/PDGFR inhibtor<\/td>\n<\/tr>\n
    A3881<\/td>\nToll-like receptor modulator<\/td>\n926927-42-6<\/td>\n98.00%<\/td>\nTLR antagonist<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

     <\/p>\n","protected":false},"excerpt":{"rendered":"

    \u816b\u7624\u58de\u6b7b\u56e0\u5b50\u6291\u5236\u5291\u7cfb\u5217\u5546\u54c1->>TAPI-1 APExBIO Technology LLC \u662f\u4e00\u5bb6 […]<\/p>\n","protected":false},"author":3,"featured_media":51043,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[5368,486],"tags":[4954],"_links":{"self":[{"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/34285"}],"collection":[{"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34285"}],"version-history":[{"count":6,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/34285\/revisions"}],"predecessor-version":[{"id":53806,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/34285\/revisions\/53806"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/media\/51043"}],"wp:attachment":[{"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34285"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34285"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34285"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}